{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:01:17Z","timestamp":1784916077368,"version":"3.55.0"},"reference-count":18,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2026,7,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In 2025, England commenced doxycycline postexposure prophylaxis (doxyPEP) for people at elevated syphilis risk and a 4CMenB vaccination programme for gonorrhoea prevention. We examine early adoption of these new preventative interventions within a community sample.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analysed data from \u2018Reducing inequalities in Sexual Health\u2019, an online community survey of men and gender-diverse people who have sex with men, conducted in November\u2013December 2025. We describe doxyPEP use (past 3\u20134 months) and 4CMenB vaccination (\u22651\u2009dose ever) among England-resident participants, including those reporting suggested eligibility criteria under national guidance (\u22655\u2009male condomless anal sex partners and\/or a recent bacterial sexually transmitted infection diagnosis, herein \u2018intervention-eligible\u2019). Among intervention-eligible participants, associations between doxyPEP use and 4CMenB vaccination with sociodemographic characteristics, clinical and behavioural history and well-being measures were assessed using Pearson\u2019s \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1518 England-resident participants (87% white; median age 49 years (IQR 38\u201359)), 18% reported doxyPEP use (95%\u2009CI 16% to 20%; 279\/1518) and 21% reported 4CMenB vaccination (95% CI 19% to 23%; 318\/1518). Of 421 intervention-eligible participants (28%), 39% reported doxyPEP use (95%\u2009CI 35% to 44%; 165\/421) and 41% reported 4CMenB vaccination (95%\u2009CI 36% to 46%; 173\/421). DoxyPEP use and 4CMenB vaccination among those offered these interventions were high (exceeding 88% in those intervention-eligible). Among intervention-eligible participants, doxyPEP use was significantly higher (p&lt;0.05) among London residents (50% vs 35% outside London), those with degree-level education (46% vs 30%) and those employed (43% vs 31%). 4CMenB vaccination was largely consistent across subgroups except by age (45% in \u226545 year-olds vs 24% in 16\u201329\u2009year-olds). Those reporting recent HIV pre-exposure prophylaxis use were more likely to report adoption of both interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings indicate substantial early adoption of doxyPEP and 4CMenB vaccination in England, with early 4CMenB vaccination appearing more uniform relative to doxyPEP. Ongoing monitoring is essential to identify emerging inequities and to understand factors driving them as rollout progresses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/sextrans-2026-057007","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:20:35Z","timestamp":1784913635000},"page":"sextrans-2026-057007","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["New era in STI prevention: early adoption of doxyPEP and 4CMenB vaccination among a community sample of men and gender-diverse people having sex with men in England\u2014findings from a large, cross-sectional survey in 2025"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1900-8892","authenticated-orcid":false,"given":"Dana","family":"Ogaz","sequence":"first","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1741-1449","authenticated-orcid":false,"given":"Dolores","family":"Mullen","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Habib Meriggi","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Hoerst","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reid","sequence":"additional","affiliation":[{"name":"The National Institute for Health and Care Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London, in partnership with the UK Health Security Agency, London, UK"},{"name":"Institute for Global Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Jayes","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Yung","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erna","family":"Buitendam","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8848-7938","authenticated-orcid":false,"given":"Natasha","family":"Ratna","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Checchi","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-2476","authenticated-orcid":false,"given":"Shamez N","family":"Ladhani","sequence":"additional","affiliation":[{"name":"Immunisation & Vaccine Preventable Diseases, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenda","family":"Hughes","sequence":"additional","affiliation":[{"name":"UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M","family":"Lowndes","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Mandal","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Weil","sequence":"additional","affiliation":[{"name":"The Love Tank, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Nutland","sequence":"additional","affiliation":[{"name":"The Love Tank, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4220-5034","authenticated-orcid":false,"given":"Catherine H","family":"Mercer","sequence":"additional","affiliation":[{"name":"The National Institute for Health and Care Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London, in partnership with the UK Health Security Agency, London, UK"},{"name":"Institute for Global Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-403X","authenticated-orcid":false,"given":"Helen","family":"Fifer","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3020-9916","authenticated-orcid":false,"given":"John","family":"Saunders","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2060-7286","authenticated-orcid":false,"given":"Hamish","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072410202445000_sextrans-2026-057007v1.1","unstructured":"Migchelsen SJ , Daahir U , Macdonald C , et al . Sexually transmitted infections and screening for chlamydia in England: 2024 report. 2025. Available: https:\/\/www.gov.uk\/government\/statistics\/sexually-transmitted-infections-stis-annual-data-tables [Accessed 1 Aug 2025]."},{"key":"2026072410202445000_sextrans-2026-057007v1.2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(25)00085-4","article-title":"Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension","volume":"25","author":"Luetkemeyer","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026072410202445000_sextrans-2026-057007v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00031-8"},{"key":"2026072410202445000_sextrans-2026-057007v1.4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/09564624251352053","article-title":"British Association for Sexual Health and HIV (BASHH) UK national guideline for the use of doxycycline post-exposure prophylaxis (DoxyPEP) for the prevention of syphilis, 2025","volume":"36","author":"Saunders","year":"2025","journal-title":"Int J STD AIDS"},{"key":"2026072410202445000_sextrans-2026-057007v1.5","unstructured":"NHS England . Introduction of new routine mpox and 4cmenb for gonorrhoea vaccination programmes letter. 2025. Available: https:\/\/www.gov.uk\/government\/publications\/introduction-of-new-routine-mpox-and-4cmenb-for-gonorrhoea-vaccination-programmes-letter\/introduction-of-new-routine-mpox-and-4cmenb-for-gonorrhoea-vaccination-programmes-letter [Accessed 18 Aug 2025]."},{"key":"2026072410202445000_sextrans-2026-057007v1.6","doi-asserted-by":"crossref","DOI":"10.2196\/publichealth.9010","article-title":"The Acceptability and Feasibility of Implementing a Bio-Behavioral Enhanced Surveillance Tool for Sexually Transmitted Infections in England: Mixed-Methods Study","volume":"4","author":"Wayal","year":"2018","journal-title":"JMIR Public Health Surveill"},{"key":"2026072410202445000_sextrans-2026-057007v1.7","unstructured":"The National Survey of Sexual Attitudes and Lifestyles (Natsal). Available: https:\/\/www.natsal.ac.uk\/ [Accessed 16 Dec 2024]."},{"key":"2026072410202445000_sextrans-2026-057007v1.8","doi-asserted-by":"crossref","first-page":"e790","DOI":"10.1016\/S2352-3018(23)00256-4","article-title":"HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment","volume":"10","author":"Sullivan","year":"2023","journal-title":"Lancet HIV"},{"key":"2026072410202445000_sextrans-2026-057007v1.9","unstructured":"UK Health Security Agency . National immunisation programme health equity 2025. 2026. Available: https:\/\/www.gov.uk\/government\/publications\/national-immunisation-programme-health-equity-audit-2025\/national-immunisation-programme-health-equity-audit-2025 [Accessed 16 Mar 2026]."},{"key":"2026072410202445000_sextrans-2026-057007v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-024-01023-3"},{"key":"2026072410202445000_sextrans-2026-057007v1.11","doi-asserted-by":"crossref","unstructured":"Seib KL , Donovan B , Jin F , et al . Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection. N Engl J Med 2026. doi:10.1056\/NEJMoa2516739","DOI":"10.1056\/NEJMoa2516739"},{"key":"2026072410202445000_sextrans-2026-057007v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00236-6"},{"key":"2026072410202445000_sextrans-2026-057007v1.13","doi-asserted-by":"crossref","unstructured":"Thng C , Eskandari S , Jin F , et al . Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO). NPJ Vaccines 2026. doi:10.1038\/s41541-026-01422-y","DOI":"10.1038\/s41541-026-01422-y"},{"key":"2026072410202445000_sextrans-2026-057007v1.14","unstructured":"UK Health Security Agency. Surveillance of targeted 4CMenB vaccination to protect individuals at higher risk of gonorrhoea 2025, Available: https:\/\/www.gov.uk\/government\/publications\/surveillance-of-4cmenb-vaccination-to-protect-individuals-at-higher-risk-of-gonorrhoea\/surveillance-of-targeted-4cmenb-vaccination-to-protect-individuals-at-higher-risk-of-gonorrhoea"},{"key":"2026072410202445000_sextrans-2026-057007v1.15","unstructured":"UK Health Security Agency . STI quarterly surveillance reports: provisional data 2026. 2026. Available: https:\/\/www.gov.uk\/government\/publications\/sti-quarterly-surveillance-reports-provisional-data [Accessed 7 May 2026]."},{"key":"2026072410202445000_sextrans-2026-057007v1.16","doi-asserted-by":"publisher","DOI":"10.3201\/eid3005.230676"},{"key":"2026072410202445000_sextrans-2026-057007v1.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-023-15779-5","article-title":"COVID-19 infection and vaccination uptake in men and gender-diverse people who have sex with men in the UK: analyses of a large, online community cross-sectional survey (RiiSH-COVID) undertaken November-December 2021","volume":"23","author":"Ogaz","year":"2023","journal-title":"BMC Public Health"},{"key":"2026072410202445000_sextrans-2026-057007v1.18","unstructured":"Local Government Association . Breaking point: securing the future of sexual health services. 2022. Available: https:\/\/www.local.gov.uk\/publications\/breaking-point-securing-future-sexual-health-services [Accessed 16 Mar 2026]."}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2026-057007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:20:39Z","timestamp":1784913639000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2026-057007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":18,"alternative-id":["10.1136\/sextrans-2026-057007"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2026-057007","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}